Co-Diagnostics Expands Vector Control Marketing Nationwide
October 15 2019 - 6:30AM
Business Wire
Vector Smart™ products being presented at 6
vector control conferences in October to prepare for 2020 mosquito
season
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that
their Vector Smart™ mosquito testing products will be presented
across the country at vector control conferences in 6 different
states this month, in preparation for the 2020 mosquito season.
Mosquito abatement districts (MADs) are publicly-funded
departments at the city, county, and state level responsible for
controlling mosquito populations, and many of the 1,000 MADs
throughout North America determine their annual budgets in Q4 of
the preceding year. The conferences being attended by the Company
this month take place in Texas, Georgia, Idaho, Nebraska, Ohio, and
Utah, each of which includes representatives from MADs in several
of the surrounding states and Canadian provinces.
Co-Diagnostics’ line of polymerase chain reaction (PCR)
multiplex assays for mosquito populations include a test for West
Nile virus (WNV), St. Louis encephalitis and western equine
encephalitis (WEE); a test for Zika, dengue and chikungunya, which
launched earlier this month and for which sales have already begun;
and another multiplex that the Company says will be ready by the
Spring 2020 mosquito season which includes eastern equine
encephalitis (EEE) instead of WEE. WNV is now found in every state
in the continental US, and human cases of EEE, a mosquito-borne
disease that kills roughly one-third of those infected and
typically leaves survivors with “mild to severe brain damage”
according to the CDC, were found in seven states this year as
well.
Dwight Egan, CEO of Co-Diagnostics, remarked, “Attending
conferences and presenting the quality and value of our vector
control products directly to those in charge of determining budgets
for mosquito abatement programs is an important step in our
go-to-market strategy for this vertical. Likewise, finding new
methods of identifying pathogens in mosquito populations is
critical for MADs to improve their own efficiency in preventing the
transmission of diseases to humans and livestock. With some of the
only tests of their kind being offered to this market, we believe
that the role Co-Diagnostics products play in these efforts will
continue to grow.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191015005414/en/
Andrew Benson Head of Investor Relations +1 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024